Dr. Julie Vose to Assume ASCO Presidency at Annual Business Meeting

Apr 27, 2015

At the Annual Business Meeting held in conjunction with the ASCO Annual Meeting, Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, will succeed Peter Paul Yu, MD, FACP, FASCO as ASCO President.

AC: What do you remember about your first ASCO Annual Meeting?

Dr. Vose: That would have been many years ago, way back when I was a fellow. I presented an abstract at an Oral Abstract Session. I remember being extremely nervous about being in front of a huge audience, but I also remember it being a great experience. Everyone at ASCO made me feel so comfortable. As a presenter, it was clear how much work goes into organizing the Meeting. I’m thankful that it’s an experience I’ve been able to recreate over many years since then.

AC: Do you have any advice for someone presenting their research for the first time at the 2015 Annual Meeting?

Dr. Vose: Practice in front of all kinds of audiences. Get lots of critiques from people inside and outside your program. You become so familiar with your own material that it’s hard to tell if you’ve missed something, so get as many eyes on the presentation as you can before the Meeting.

AC: What sessions are you particularly excited about attending this year?

Dr. Vose: I’m excited about the new Global Oncology Symposium, where we’ll take a close look at oncology practice beyond the United States. I’m also looking forward to some of the sessions on patient access to care and models of supportive care—I hope I have time to attend them! I am also looking forward to speaking at and participating in the Woman’s Networking Center—it will be a great addition to the Annual Meeting.

AC: How have you been preparing for your term as ASCO President?

Dr. Vose: I have been attending as many ASCO committee and task force meetings as I can, in order to meet committee leaders and to become familiar with the work they’re doing. I’ve been doing a lot more reading on topics outside of oncology: government relations, networking, economics, practice management.

AC: What will be some of your first priorities when your term begins?

Dr. Vose: My theme is going to be related to patient-centered care and research. There will be a focus on the collective wisdom of the multidisciplinary care team, in which every member plays an important role in the patient’s care. We’ll be looking at ways to make the clinical trials system more accessible and more affordable for patients. We want all patients, regardless of their insurance situation, to have access to clinical trials. Value will continue to be an important topic of conversation, in making sure that our patients receive excellent care without excess financial toxicity.

CancerLinQ™ will see major developments over the next year, as we build out the full prototype and get our vanguard practices up to speed. We want to make sure that we capture information and learn something new from every patient encounter.

Making sure that we’re investing wisely in cancer research is also a priority. Our research enterprise needs to be efficient and powerful, so that we can bring new treatments forward for patients.

Back to Top